Clik here to view.
Frazier Life Sciences团队迎来资深研发领导人
加州门洛帕克 –(美国商业资讯)–Frazier Life Sciences宣布大英帝国官佐勋章(OBE)获得者、英国皇家化学会会士Annette Doherty博士加入公司并担任高级顾问。她拥有35年在国际市场担任化学专家和药物研发部门领导的丰富经验，直接参与领导了30多种新药的开发和上市，涵盖呼吸系统、传染病、肿瘤学和免疫学等一系列治疗领域。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
フレーザー・ライフ・サイエンシズがシニア研究開発リーダーをチームに迎える
米カリフォルニア州メンローパーク （ビジネスワイヤ） — フレーザー・ライフ・サイエンシズは、アネット・ドハティ（Ph.D.、OBE、FRSC）をシニアアドバイザーに迎えたと発表しました。ドハティ博士は、化学者および医薬品研究開発部門のリーダーとして35年の国際経験を持ち、呼吸器、感染症、オンコロジー、免疫を含むさまざまな治療領域で新薬30種以上の開発・上市の主導に直接関与してきました。...
View ArticleClik here to view.
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients...
RAHWAY, N.J. AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved by the Japan Pharmaceuticals and Medical Devices Agency...
View ArticleClik here to view.
AdvanCellがモーニングサイド主導のシリーズB資金調達で1800万豪ドルの調達を完了
シドニー （ビジネスワイヤ） — 革新的ながん治療法である標的α線治療のプラットフォーム技術を有するオーストラリアの放射性医薬品企業AdvanCellは本日、モーニングサイドが主導するシリーズBの資金調達で1800万豪ドルを調達したと発表しました。 AdvanCellの最高経営責任者（CEO）で創設者のAndrew...
View ArticleClik here to view.
Genome Insight and Ajou University Medical Center Launch Program to Apply...
SAN DIEGO Genome Insight, a cancer whole genome platform company, is launching a pilot program in Ajou University Medical Center to test the use of Whole Genome Sequencing (WGS) in routine cancer...
View ArticleClik here to view.
GICELL Announces Research Collaboration with HK inno.N for next-generation...
SEOUL, South Korea GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. This press release features multimedia. View the full...
View ArticleClik here to view.
百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准
中国北京与美国圣地亚哥 (美国商业资讯)–百奥赛图（北京）医药科技股份有限公司（“百奥赛图”）与TRACON Pharmaceuticals (“TRACON”，纳斯达克股票代码：TCON)，共同宣布美国食品药品监督管理局（FDA）批准开展YH001、恩沃利单抗（envafolimab）及阿霉素联合治疗软组织肉瘤病人，包括先前未接受过治疗的病人的临床1/2期研究。...
View ArticleClik here to view.
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of...
BEIJING & SAN DIEGO Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug...
View ArticleClik here to view.
Epredia Launches Laser Cassette Printers Designed to Improve Sample Tracking...
PORTSMOUTH, N.H. Epredia, a global leader in precision cancer diagnostics, today announced that it has launched U.S. sales of two state-of-the-art printers used in laboratories to identify and track...
View ArticleClik here to view.
肉腫患者のフロントライン治療でCTLA-4抗体YH001とエンバフォリマブの併用を検討するINDを米国FDAが承認
北京 & サンディエゴ （ビジネスワイヤ） — バイオサイトジェン・ファーマシューティカルズ（北京）（以下、「バイオサイトジェン」）とトラコン・ファーマシューティカルズ（Nasdaq:...
View ArticleClik here to view.
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government...
View ArticleClik here to view.
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP...
SHANGHAI CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces...
View ArticleClik here to view.
Bertis Announces Proteomic Based Research Results of New Biomarker for...
SEONGNAM, South Korea Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced on the 5th that the research results of their...
View ArticleClik here to view.
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that BTK inhibitor orelabrutinib has been granted...
View ArticleClik here to view.
Orum Therapeutics to Participate at Investor Conferences in September
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Lenalidomide Capsules in the...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today...
View ArticleClik here to view.
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3...
PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J. Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering...
View ArticleClik here to view.
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and...
View ArticleClik here to view.
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View Article